Intracoronary cardiosphere-derived stem cell therapy - Capricor

Drug Profile

Intracoronary cardiosphere-derived stem cell therapy - Capricor

Alternative Names: CAP-1001; CPI-003; CPI-003 - Capricor

Latest Information Update: 03 Jan 2014

Price : $50

At a glance

  • Originator Capricor
  • Developer Capricor Therapeutics; Cedars-Sinai Health System; Johns Hopkins University School of Medicine
  • Class Cardiovascular therapies; Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Myocardial infarction

Most Recent Events

  • 31 Dec 2013 No development reported - Phase-I for Myocardial infarction in USA (Intracoronary)
  • 21 Nov 2013 Nile Therapeutics has merged with Capricor to form Capricor Therapeutics
  • 16 Aug 2011 Phase I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top